Literature DB >> 18408831

Tear film and ocular surface alterations in chronic users of antiglaucoma medications.

Lina do Prado Baffa1, Jose Reinaldo da Silva Ricardo, Ana Carolina Dias, Carolina Maria Módulo, Alexandre Martins Braz, Jayter Silva de Paula, Maria de Lourdes Veronese Rodrigues, Eduardo Melani Rocha.   

Abstract

PURPOSE: Tear film can be altered by chronic medications that may disrupt the equilibrium responsible for the functioning of the lacrimal gland and ocular surface. The purpose of this study was to determine if antiglaucomatous chronic treatment induced alterations in the tear film and ocular surface.
METHODS: After informed consent, 21 patients using antiglaucomatous eye drops for more than 8 months and 20 age- and sex-matched volunteers without eye and systemic medications (control group) were enrolled. The data of ocular discomfort, fluorescein and lisamine green staining, tear film break-up time and Schirmer test were collected and compared by Student's t test. The impression cytology data were graded and compared by chi-square test.
RESULTS: Patients chronically using antiglaucomatous medications presented with significant higher fluorescein staining (p=0.003), lisamine green staining (p=0.02) and lower TFBUT (p=0.001). The other compared parameters, including impression cytology were similar between the treated and control group (p>0.05).
CONCLUSIONS: The present study shows that the tear film and the ocular surface are altered in patients under antiglaucomatous medications. In common, all medications were preserved with benzalkonium chloride. Efforts to minimize the adverse effects of chronic use of antiglaucomatous drugs must be addressed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18408831     DOI: 10.1590/s0004-27492008000100004

Source DB:  PubMed          Journal:  Arq Bras Oftalmol        ISSN: 0004-2749            Impact factor:   0.872


  11 in total

1.  Nanovesicular formulation of brimonidine tartrate for the management of glaucoma: in vitro and in vivo evaluation.

Authors:  Sabyasachi Maiti; Sayon Paul; Ranjit Mondol; Somasree Ray; Biswanath Sa
Journal:  AAPS PharmSciTech       Date:  2011-06-14       Impact factor: 3.246

2.  Clinical and laboratory evaluation of sicca complaints: distinctive aspects of primary, secondary and non-Sjogren syndrome.

Authors:  Fabíola Reis de Oliveira; Ana Carolina F Motta; Carolina Maria Módulo; Denny Marcos Garcia; John A Chiorini; Paulo Louzada-Junior; Eduardo Melani Rocha
Journal:  Adv Rheumatol       Date:  2022-07-01

Review 3.  Preservative toxicity in glaucoma medication: clinical evaluation of benzalkonium chloride-free 0.5% timolol eye drops.

Authors:  Lauren M Rosin; Nicholas P Bell
Journal:  Clin Ophthalmol       Date:  2013-10-30

4.  Evaluation of Ocular Surface Disease in Asian Patients with Primary Angle Closure.

Authors:  Tan Ee Ling; Khairuddin Othman; Ong Poh Yan; Rasdi Abdul Rashid; Cheong Min Tet; Azhany Yaakob; Liza-Sharmini Ahmad Tajudin
Journal:  Open Ophthalmol J       Date:  2017-02-28

5.  Is Sjögren's syndrome dry eye similar to dry eye caused by other etiologies? Discriminating different diseases by dry eye tests.

Authors:  Denny Marcos Garcia; Fabiola Reis de Oliveira; Carolina Maria Módulo; Jacqueline Faustino; Amanda Pires Barbosa; Monica Alves; Eduardo Melani Rocha
Journal:  PLoS One       Date:  2018-12-03       Impact factor: 3.240

Review 6.  The impact of topical intraocular pressure lowering medications on the ocular surface of glaucoma patients: A review.

Authors:  Kofi Asiedu; Sampson Listowell Abu
Journal:  J Curr Ophthalmol       Date:  2018-09-01

7.  Extracellular MMP-9-Based Assessment of Ocular Surface Inflammation in Patients with Primary Open-Angle Glaucoma.

Authors:  Anna Zaleska-Żmijewska; Ewa Strzemecka; Zbigniew M Wawrzyniak; Jacek P Szaflik
Journal:  J Ophthalmol       Date:  2019-04-03       Impact factor: 1.909

Review 8.  Oxidative Stress in the Protection and Injury of the Lacrimal Gland and the Ocular Surface: are There Perspectives for Therapeutics?

Authors:  Camila Nunes Lemos; Lilian Eslaine Costa Mendes da Silva; Jacqueline Ferreira Faustino; Marina Zilio Fantucci; Adriana de Andrade Batista Murashima; Leidiane Adriano; Monica Alves; Eduardo Melani Rocha
Journal:  Front Cell Dev Biol       Date:  2022-03-11

9.  Ocular surface evaluation in patients treated with a fixed combination of prostaglandin analogues with 0.5% timolol maleate topical monotherapy: a randomized clinical trial.

Authors:  Heloisa Helena Russ; Pedro Antônio Nogueira-Filho; Jeison de Nadai Barros; Nubia Vanessa Lima de Faria; Fabiano Montiani-Ferreira; José Álvaro Pereira Gomes; Paulo Augusto Arruda Mello
Journal:  Clinics (Sao Paulo)       Date:  2013-10       Impact factor: 2.365

10.  Symptoms and signs of ocular surface disease related to topical medication in patients with glaucoma.

Authors:  Barbara Cvenkel; Špela Štunf; Irena Srebotnik Kirbiš; Margareta Strojan Fležar
Journal:  Clin Ophthalmol       Date:  2015-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.